Phase 1 N=58 Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients
Hepatitis C
Primary: Evaluation of Safety. — 6; 8; 9; 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=39 A Study of IMC-RON8 in Advanced Solid Tumors
Cancer
Primary: Maximum Tolerated Dose (MTD) of IMC-RON8 — NA mg/kg
Phase 1 N=24 Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects
Chronic Obstructive Pulmonary Disease
Primary: Number of Participants With ≥1 Treatment Emergent Adverse Event in Any Category. — 3; 1; 5; 4 Participants
Phase 1 N=88 Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study
Healthy Volunteers
Primary: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) — 0; 16.7; 33.3; 16.7 percentage of participants
Phase 1 N=11 Safety of NStride Autologous Protein Solution in the Treatment of Knee Osteoarthritis (PROGRESS I)
Osteoarthritis, Knee
Primary: Adverse Events — 27; 1 events
Phase 1 N=63 Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients
Hepatitis C, Treatment Naïve, Genotype 1 Patients
Primary: At Least 1 TEAE — 2; 12; 12; 12 Participants
Phase 1 N=41 A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen
Advanced Solid Tumors · Adenocarcinoma of the Prostate
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 6; 15; 5; 3 participants
Phase 1 N=56 Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy Adults
Healthy Volunteer
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 10; 1; 1; 5 Participants
Phase 1 N=43 Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010)
Proven or Suspected Gram-negative Bacterial Infection · Peri-operative Prophylaxis
Primary: Maximum Plasma Concentration (Cmax) of Ceftolozane — 63.5; 56.2; 51.4; 96.6 μg/mL
Phase 1 N=72 Single-Dose Phase 1 Study of TAK-792
Healthy Male Adults Participants
Primary: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) — 16.7; 16.7; 0.0; 33.3 percentage of participants
Phase 1 N=48 A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus Vaccine
Rotavirus Infection
Primary: Maximum Severity of Adverse Events After Any Vaccination — 1; 2; 0; 2 Participants — p=0.44
Phase 1 N=15 HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer
Breast Cancer
Primary: Rate of Treatment Regimen Completion — 14 Participants
Phase 1 N=13 Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Number of Patients With Treatment-emergent Adverse Events — 12; 6; 6; 12 Participants
Phase 1 N=27 HEMOBLAST Pilot Clinical Investigation
Hemostasis
Primary: Mean Paired Kappa Statistic for the Assignment of SBSS Scores by 2 Investigators — 0.7754 Kappa statistic
Phase 1 N=37 Plasma Pharmacokinetics (PK) & Lung Penetration of Ceftolozane/Tazobactam in Participants With Pneumonia (MK-7625A-007)
Critically Ill · Pneumonia
Primary: Maximum Plasma Concentration (Cmax) of Ceftolozane or Tazobactam in Mechanically Ventilated Participants for the First and Last Dose of Ceftolozane/Tazobactam Treatment…